Nurify Medical

Overview

The clinic operates under the Nurify Medical group and provides specialist medical treatment for people with treatment-resistant depression. The London Esketamine Clinic was an early private provider in the UK to offer Esketamine (Spravato®) nasal spray from September 2020, delivering supervised, clinic-based administration under consultant psychiatric oversight.

The clinic emphasises medically supervised, evidence-informed care for people who have not responded adequately to multiple antidepressant trials. Their team of consultant psychiatrists assess eligibility and manage the treatment pathway, combining pharmacological oversight with clinical follow-up.

Best for

This clinic is best suited for adults with moderate to severe treatment-resistant depression who are seeking a medically supervised esketamine nasal spray treatment option. Typical clients are those who have had insufficient response to two or more antidepressant treatments and are looking for specialist psychiatric assessment and on-site administration.

• Adults with treatment-resistant depression
• People requiring supervised, in-clinic administration of esketamine

Approach

The practice begins with a clinical assessment conducted by consultant psychiatrists to confirm diagnosis and suitability for esketamine. Initial enquiries can be made online or by phone, after which the team arranges a formal psychiatric assessment.

Esketamine is administered as a nasal spray device and is provided exclusively within the clinic under direct clinician supervision. The clinical pathway includes pre-treatment assessment, supervised dosing sessions, and post-dose monitoring to ensure safety and tolerability.

The clinic integrates medical monitoring and psychiatric follow-up, with clinicians adjusting treatment plans according to response and side-effect profile. Care is delivered in a medically regulated environment with protocols consistent with MHRA guidance for Spravato® administration.

Education and Training

The clinical team is composed of consultant psychiatrists and clinicians experienced in neuromodulation and medication-assisted psychiatric care. The service highlights regulatory compliance and links to external accreditation and inspection bodies.

Support

Clients receive structured supervision during dosing sessions with clinical monitoring before, during and after administration. Safety protocols and monitoring are emphasised given the nature of esketamine treatment.

The clinic provides a pathway of assessment, supervised treatment sessions and clinical follow-up. Preparatory information, consent processes and post-session observation are part of the standard care model to manage adverse effects and ensure patient safety.

Services reference external review platforms and regulatory inspection (CQC) as part of transparency about quality and patient feedback.

Practical details

Initial enquiries are accepted via an online form or by telephone; assessment is arranged with a consultant psychiatrist. Esketamine dosing is delivered in-person at the clinic sites in Harley Street, London. Sessions are supervised and cannot be self-administered at home.

• Format: Hybrid (online enquiries/consultation arrangements + in-person dosing)
• Locations: 100 Harley Street, London W1G 7JA; 10 Harley Street, London W1G 9PF
• Languages: English

This description was generated based on information from the official website and other materials provided by the provider.